These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 16484292)

  • 1. NICE risk factors for gastrointestinal adverse events in diclofenac users in general practice in Germany: comment on the article of Thompson et al.
    Zeidler H; May M; Uberall MA; Vergin H
    Rheumatology (Oxford); 2006 Apr; 45(4):494-5. PubMed ID: 16484292
    [No Abstract]   [Full Text] [Related]  

  • 2. Long-term NSAID use in primary care: changes over a decade and NICE risk factors for gastrointestinal adverse events.
    Thompson PW; Tee L; McBride J; Quincey D; Strat Liddiard G
    Rheumatology (Oxford); 2005 Oct; 44(10):1308-10. PubMed ID: 15972345
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Etoricoxib: new drug. Avoid using cox-2 inhibitors for pain.
    Prescrire Int; 2007 Dec; 16(92):223-7. PubMed ID: 18084859
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative assessment of the gastrointestinal and cardiovascular risk-benefit of celecoxib compared to individual NSAIDs at the population level.
    Varas-Lorenzo C; Maguire A; Castellsague J; Perez-Gutthann S
    Pharmacoepidemiol Drug Saf; 2007 Apr; 16(4):366-76. PubMed ID: 16897817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. NSAIDs, risks, and gastroprotective strategies: current status and future.
    Graham DY; Chan FK
    Gastroenterology; 2008 Apr; 134(4):1240-6. PubMed ID: 18395101
    [No Abstract]   [Full Text] [Related]  

  • 6. Physicians' approaches to the use of gastroprotective strategies in low-risk non-steroidal anti-inflammatory drug users.
    Murthy SK; Kauldher S; Targownik LE
    Aliment Pharmacol Ther; 2006 May; 23(9):1365-72. PubMed ID: 16629943
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hospitalization for gastrointestinal adverse events attributable to the use of low-dose aspirin among patients 50 years or older also using non-steroidal anti-inflammatory drugs: a retrospective cohort study.
    Rahme E; Nedjar H; Bizzi A; Morin S
    Aliment Pharmacol Ther; 2007 Nov; 26(10):1387-98. PubMed ID: 17892525
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gastrointestinal tract disorder as a side effect of non-steroidal anti inflammatory drugs (NSAIDs).
    Simadibrata M
    Acta Med Indones; 2004; 36(4):195-6. PubMed ID: 15931719
    [No Abstract]   [Full Text] [Related]  

  • 9. The balance between severe cardiovascular and gastrointestinal events among users of selective and non-selective non-steroidal anti-inflammatory drugs.
    van der Linden MW; van der Bij S; Welsing P; Kuipers EJ; Herings RM
    Ann Rheum Dis; 2009 May; 68(5):668-73. PubMed ID: 18495734
    [TBL] [Abstract][Full Text] [Related]  

  • 10. NSAID toxicity: where are we and how do we go forward?
    Hawkey CJ
    J Rheumatol; 2002 Apr; 29(4):650-2. PubMed ID: 11950001
    [No Abstract]   [Full Text] [Related]  

  • 11. Comparison of two different dosages of celecoxib with diclofenac for the treatment of active ankylosing spondylitis: results of a 12-week randomised, double-blind, controlled study.
    Sieper J; Klopsch T; Richter M; Kapelle A; Rudwaleit M; Schwank S; Regourd E; May M
    Ann Rheum Dis; 2008 Mar; 67(3):323-9. PubMed ID: 17616556
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [A step back or training pain?].
    Raeder J
    Tidsskr Nor Laegeforen; 2005 Aug; 125(15):2050-1. PubMed ID: 16100553
    [No Abstract]   [Full Text] [Related]  

  • 13. Ecthyma gangrenosum presenting in diclofenac induced neutropenia.
    Fairhurst DA; Pollock B
    J Eur Acad Dermatol Venereol; 2006 Aug; 20(7):868-9. PubMed ID: 16898913
    [No Abstract]   [Full Text] [Related]  

  • 14. Economic comparison of nimesulide and diclofenac, and the incidence of adverse events in the treatment of rheumatic disease in Greece.
    Liaropoulos L
    Rheumatology (Oxford); 1999 May; 38 Suppl 1():39-46. PubMed ID: 10369405
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arthrotec, diclofenac and ibuprofen in general practice.
    Kiff PS; Stead H; Morant SV; Shield MJ
    Eur J Rheumatol Inflamm; 1994; 14(3 Suppl):31-8. PubMed ID: 7556344
    [No Abstract]   [Full Text] [Related]  

  • 16. Simultaneous assessment of short-term gastrointestinal benefits and cardiovascular risks of selective cyclooxygenase 2 inhibitors and nonselective nonsteroidal antiinflammatory drugs: an instrumental variable analysis.
    Schneeweiss S; Solomon DH; Wang PS; Rassen J; Brookhart MA
    Arthritis Rheum; 2006 Nov; 54(11):3390-8. PubMed ID: 17075817
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Measuring quality in arthritis care: the Arthritis Foundation's quality indicator set for analgesics.
    Saag KG; Olivieri JJ; Patino F; Mikuls TR; Allison JJ; MacLean CH
    Arthritis Rheum; 2004 Jun; 51(3):337-49. PubMed ID: 15188317
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post-marketing surveillance study of Voltarol 75 mg SR in the primary care setting.
    Jones CW
    Br J Clin Pract; 1996; 50(7):390-5. PubMed ID: 9015913
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Minimizing risks of NSAIDs: cardiovascular, gastrointestinal and renal.
    Davies NM; Reynolds JK; Undeberg MR; Gates BJ; Ohgami Y; Vega-Villa KR
    Expert Rev Neurother; 2006 Nov; 6(11):1643-55. PubMed ID: 17144779
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug-induced Pseudomonas aeruginosa ecthyma gangrenosum.
    del Giudice P
    J Eur Acad Dermatol Venereol; 2007 Feb; 21(2):289. PubMed ID: 17243992
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.